The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Discovery and mechanism of ustekinumab: A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders
Open accessAbstract
Monoclonal antibody (mAb) therapy was first established upon the approval of a mouse antibody for treatment of human acute organ rejection. However, the high incidence of immune response against the mouse mAb restricted therapeutic utility. Development of chimeric, "humanized" and human mAbs broadened therapeutic application to immune-mediated diseases requiring long-term treatment. Indeed, mAb therapeutics targeting soluble cytokines are highly effective in numerous immune-mediated disorders. A recent example is ustekinumab, a first-in-class therapeutic human immunoglobulin G1 kappa mAb that binds to the interleukins (IL)-12 and IL-23, cytokines that modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets. Ustekinumab was generated via recombinant human IL-12 immunization of human immunoglobulin (hu-Ig) transgenic mice. Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor β1 subunit of the IL-12 and IL-23 receptor complexes. Ustekinumab is approved for treatment of moderate-to-severe plaque psoriasis and has demonstrated efficacy in Crohn disease and psoriatic arthritis. The clinical characterization of ustekinumab continues to clarify our understanding of human immune pathologies and may offer a novel therapeutic option for certain immune-mediated diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A., & Coffman, R. L. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.7.2348 · Cited by 7,506
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene
Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Fiorentino, D. F., Bond, M. W., & Mosmann, T. R. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.6.2081 · Cited by 2,733
Development, cytokine profile and function of human interleukin 17-producing helper T cells
Wilson, N. J., Boniface, K., Chan, J. R., McKenzie, B. S., Blumenschein, W. M., Mattson, J. D., Basham, B., Smith, K., Chen, T., Morel, F., et al. (2007) · Nature Immunology · doi:10.1038/ni1497 · Cited by 2,035
Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., & Trinchieri, G. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.827 · Cited by 1,953
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Acosta-Rodriguez, E. V., Napolitani, G., Lanzavecchia, A., & Sallusto, F. (2007) · Nature Immunology · doi:10.1038/ni1496 · Cited by 1,857
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation
Murphy, C. A., Langrish, C. L., Chen, Y., Blumenschein, W., McClanahan, T., Kastelein, R. A., Sedgwick, J. D., & Cua, D. J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030896 · Cited by 1,669
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
Tracey, D., Klareskog, L., Sasso, E. H., Salfeld, J. G., & Tak, P. P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.10.001 · Cited by 1,628
Plasticity of CD4+ T Cell Lineage Differentiation
Zhou, L., Chong, M. M. W., & Littman, D. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.001 · Cited by 1,551 · cited 7×
“Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.”
BackgroundInfluentialPapp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
Schweiger, D., Baufeld, C., Drescher, P., Oltrogge, B., Höpfner, S., Mess, A., Lüttke, J., Rippke, F., Filbry, A., & Max, H. (2013) · Skin Pharmacology and Physiology · doi:10.1159/000348473 · Cited by 1,346
Antibodies to interleukin 12 abrogate established experimental colitis in mice.
Neurath, M. F., Fuss, I., Kelsall, B. L., Stüber, E., & Strober, W. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1281 · Cited by 1,335
Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J., Pflanz, S., Zhang, R., Singh, K. P., Vega, F., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5699 · Cited by 1,296
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Cargill, M., Schrodi, S. J., Chang, M., Garcia, V. E., Brandon, R., Callis, K. P., Matsunami, N., Ardlie, K. G., Civello, D., Catanese, J. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/511051 · Cited by 1,086
Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., & Krueger, J. G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701213 · Cited by 1,082
Trifari, S., Kaplan, C. D., Tran, E. H., Crellin, N. K., & Spits, H. (2009) · Nature Immunology · doi:10.1038/ni.1770 · Cited by 1,021
Psoriasis − epidemiology and clinical spectrum
Christophers, E. (2001) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2001.00832.x · Cited by 972
Schön, M. P., & Boehncke, W.-H. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041320 · Cited by 955
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.273 · Cited by 805
Xu, L., Kitani, A., Fuss, I., & Strober, W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6725 · Cited by 733
A functional interleukin 12 receptor complex is composed of two β-type cytokine receptor subunits
Presky, D. H., Yang, H., Minetti, L. J., Chua, A. O., Nabavi, N., Wu, C.-Y., Gately, M. K., & Gubler, U. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14002 · Cited by 689
IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease
Geremia, A., Arancibia-Cárcamo, C. V., Fleming, M. P. P., Rust, N., Singh, B., Mortensen, N. J., Travis, S. P. L., & Powrie, F. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101712 · Cited by 640
Follicular B helper T cells in antibody responses and autoimmunity
Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1714 · Cited by 624
Gottlieb, A., Menter, A., Mendelsohn, A., Shen, Y.-K., Li, S., Guzzo, C., Fretzin, S., Kunynetz, R., & Kavanaugh, A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60140-9 · Cited by 585
Monteleone, G., Biancone, L., Marasco, R., Morrone, G., Marasco, O., Luzza, F., & Pallone, F. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70128-8 · Cited by 573
Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells
Staudt, V., Bothur, E., Klein, M., Lingnau, K., Reuter, S., Grebe, N., Gerlitzki, B., Hoffmann, M., Ulges, A., Taube, C., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.07.014 · Cited by 554
Lebwohl, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12954-6 · Cited by 548
Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.
Leonard, J. P., Waldburger, K. E., & Goldman, S. J. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.1.381 · Cited by 547
Segal, B. M., Constantinescu, C. S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., & Kasper, L. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70173-x · Cited by 479
Windhagen, A., Newcombe, J., Dangond, F., Strand, C., Woodroofe, M. N., Cuzner, M. L., & Hafler, D. A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1985 · Cited by 463
Human antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine
Valent, P., Groner, B., Schumacher, U., Superti-Furga, G., Busslinger, M., Kralovics, R., Zielinski, C., Penninger, J. M., Kerjaschki, D., Stingl, G., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000443526 · Cited by 409
Capon, F., Di Meglio, P., Szaub, J., Prescott, N. J., Dunster, C., Baumber, L., Timms, K., Gutin, A., Abkevic, V., Burden, A. D., et al. (2007) · Human Genetics · doi:10.1007/s00439-007-0397-0 · Cited by 408
Gran, B., Zhang, G.-X., Yu, S., Li, J., Chen, X.-H., Ventura, E. S., Kamoun, M., & Rostami, A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.12.7104 · Cited by 405
Rachitskaya, A. V., Hansen, A. M., Horai, R., Li, Z., Villasmil, R., Luger, D., Nussenblatt, R. B., & Caspi, R. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5167 · Cited by 399
Interleukin-23: A key cytokine in inflammatory diseases
Duvallet, E., Semerano, L., Assier, E., Falgarone, G., & Boissier, M.-C. (2011) · Annals of Medicine · doi:10.3109/07853890.2011.577093 · Cited by 282
High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice
Fishwild, D. M., O'Donnell, S. L., Bengoechea, T., Hudson, D. V., Harding, F., Bernhard, S. L., Jones, D., Kay, R. M., Higgins, K. M., Schramm, S. R., et al. (1996) · Nature Biotechnology · doi:10.1038/nbt0796-845 · Cited by 266
Di Meglio, P., Di Cesare, A., Laggner, U., Chu, C.-C., Napolitano, L., Villanova, F., Tosi, I., Capon, F., Trembath, R. C., Peris, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017160 · Cited by 262
Davidson, N. J., Hudak, S. A., Lesley, R., Menon, S., Leach, M. W., & Rennick, D. M. (1998) · PubMed · Cited by 250
Expression of Interleukin-12 is Increased in Psoriatic Skin
Yawalkar, N., Karlen, S., Hunger, R., Brand, C. U., & Braathen, L. R. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00446.x · Cited by 221
Davidson, N. J., Hudak, S. A., Lesley, R. E., Menon, S., Leach, M. W., & Rennick, D. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.3143 · Cited by 208
Ness-Schwickerath, K. J., Jin, C., & Morita, C. T. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000600 · Cited by 196
IL-12 and IL-18 Are Increased and Stimulate IFN-γ Production in Sarcoid Lungs
Shigehara, K., Shijubo, N., Ohmichi, M., Takahashi, R., Kon, S.-I., Okamura, H., Kurimoto, M., Hiraga, Y., Tatsuno, T., Abe, S., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.642 · Cited by 185
Prevalence and correlates of suicidal ideation among patients with skin disease
Picardi, A., Mazzotti, E., & Pasquini, P. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.11.1103 · Cited by 182
Psoriasis has a major secondary impact on the lives of family members and partners
Eghlileb, A. M., Davies, E. E. G., & Finlay, A. Y. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07881.x · Cited by 177
KRISTENSEN, M., CHU, C. Q., EEDY, D. J., FELDMANN, M., BRENNAN, F. M., & BREATHNACH, S. M. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb03457.x · Cited by 171
The family impact of skin diseases: the Greater Patient concept
Basra, M. K. A., & Finlay, A. Y. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07794.x · Cited by 170
Paul Ehrlich — in search of the magic bullet
Winau, F., Westphal, O., & Winau, R. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.04.003 · Cited by 164
O'Brien, R. L., Roark, C. L., & Born, W. K. (2009) · European Journal of Immunology · doi:10.1002/eji.200839120 · Cited by 161
Lupardus, P. J., & García, K. C. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.07.051 · Cited by 156
Yoon, C., Johnston, S. C., Tang, J. H., Stahl, M., Tobin, J. F., & Somers, W. S. (2000) · The EMBO Journal · doi:10.1093/emboj/19.14.3530 · Cited by 155
Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab
Benson, J., Sachs, C. W., Treacy, G., Zhou, H., Pendley, C. E., Brodmerkel, C. M., Shankar, G., & Mascelli, M. A. (2011) · Nature Biotechnology · doi:10.1038/nbt.1903 · Cited by 148
Self-citationVanden Eijnden, S., Goriely, S., De Wit, D., Willems, F., & Goldman, M. (2005) · European Journal of Immunology · doi:10.1002/eji.200425677 · Cited by 148
Interleukin-12, interleukin-23, and psoriasis: Current prospects
Torti, D. C., & Feldman, S. R. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.07.016 · Cited by 143
Malfait, A., Butler, D., Presky, D. H., Maini, R. N., Brennan, F. M., & Feldmann, M. (1998) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1998.00485.x · Cited by 142
Jacob, S. E., Nassiri, M., Kerdel, F. A., & Vincek, V. (2003) · Mediators of Inflammation · doi:10.1080/09629350310001619753 · Cited by 141
Koczan, D., Drynda, S., Hecker, M., Drynda, A., Guthke, R., Kekow, J., & Thiesen, H. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2419 · Cited by 120
Hong, K., Chu, A. D., Ludviksson, B. R., Berg, E. L., & Ehrhardt, R. O. (1999) · PubMed · Cited by 119
Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis
Nicoletti, F., Patti, F., Cocuzza, C. E., et al. (1996) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(96)00101-4 · Cited by 116
Hong, K., Chu, A. D., Ludviksson, B. R., Berg, E. L., & Ehrhardt, R. O. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.12.7480 · Cited by 111
Structural Basis for the Dual Recognition of IL-12 and IL-23 by Ustekinumab
Luo, J., Wu, S., Lacy, E. R., Orlovsky, Y. I., Baker, A. E., Teplyakov, A., Obmolova, G., Heavner, G. A., Richter, H.-T., & Benson, J. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.07.046 · Cited by 110
Self-citationReichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10677 · Cited by 93
Increased release of interleukin-12p40 in MS
Fassbender, K. C., Ragoschke, A., Rossol, S., Schwartz, A., Mielke, O., Paulig, A., & Hennerici, M. G. (1998) · Neurology · doi:10.1212/wnl.51.3.753 · Cited by 89
Judson, M. A., Marchell, R., Mascelli, M. A., Piantone, A., Barnathan, E. S., Petty, K. J., Chen, D., Fan, H., Grund, H., Ma, K., et al. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2011.06.017 · Cited by 85
Self-citationYeilding, N. M., Szapary, P. O., Brodmerkel, C. M., Benson, J., Plotnick, M. I., Zhou, H., Goyal, K., Schenkel, B., Giles-Komar, J. M., Mascelli, M. A., et al. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05963.x · Cited by 81
Self-citationGuttman‐Yassky, E., & Krueger, J. G. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08135.x · Cited by 72
Berrebi, D. D., Besnard, M., Fromont, G., Paris, R., Mougenot, J. F., Lagausie, P. P. D., Émilie, D., Cézard, J., Navarro, J., & Peuchmaur, M. M. (1998) · PubMed · Cited by 61
IL-23 modulates CD56+/CD3- NK Cell and CD56+/CD3+ NK-like T Cell function differentially from IL-12
van de Wetering, D., de Paus, R. A., van Dissel, J. T., & van de Vosse, E. (2008) · International Immunology · doi:10.1093/intimm/dxn132 · Cited by 58
Sandborn, W. J., Gasink, C., Gao, L.-L., BLANK, M. A., Johanns, J., Guzzo, C. A., Sands, B. E., Hanauer, S. B., Targan, S. R., Rutgeerts, P. J., et al. (2011) · Gastroenterology · doi:10.1016/s0016-5085(11)60443-5 · Cited by 29
Cited by
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Sandborn, W. J., Gasink, C., Gao, L.-L., Blank, M. A., Johanns, J., Guzzo, C., Sands, B. E., Hanauer, S. B., Targan, S., Rutgeerts, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203572 · Cited by 1,134
Hidradenitis Suppurativa: Advances in Diagnosis and Treatment
Saunte, D. M. L., & Jemec, G. B. E. (2017) · JAMA · doi:10.1001/jama.2017.16691 · Cited by 492
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Gordon, K. B., Duffin, K. C., Bissonnette, R., Prinz, J. C., Wasfi, Y., Li, S., Shen, Y.-K., Szapary, P., Randazzo, B., & Reich, K. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501646 · Cited by 306
Al-Riyami, L., Pineda, M. A., Rzepecka, J., Huggan, J. K., Khalaf, A. I., Suckling, C. J., Scott, F. J., Rodgers, D. T., Harnett, M. M., & Harnett, W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401251p · Cited by 94
Review of biologics in allergic contact dermatitis
Bhatia, J., Sarin, A., Wollina, U., Lotti, T., Navarini, A. A., Mueller, S. M., Grabbe, S., Saloga, J., Rokni, G. R., & Goldust, M. (2020) · Contact Dermatitis · doi:10.1111/cod.13584 · Cited by 25
Metadata
- Authors
- Benson, J. M., Peritt, D., Scallon, B. J., Heavner, G. A., Shealy, D. J., Giles-Komar, J. M., & Mascelli, M. A.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2011-11
- Volume
- 3
- Issue
- 6
- Pages
- 535-545
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2324298557
- Cited by
- 340
- References
- 79
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.